Internal Medicine, Hematology & Oncology · Asheville, NC
NPI
1699764878
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
551 Brevard Rd
Asheville, NC, 28806
Phone (828) 212-7021
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
130,308 services
Medicare patients, 2024
1,082
Average age 75
Drug cost, 2024
$6.4M
2,308 prescriptions
Company payments, 2025
$2,511
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher H Chay was code J9299 (injection, nivolumab, 1 mg), 14,200 times for 17 patients. In total Christopher H Chay billed 130,308 services in 159 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 14,200 | 17 | $24.63 | $350K |
| J0185 Injection, aprepitant, 1 mg | Office | 9,490 | 47 | $1.35 | $13K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 6,200 | 23 | $44.77 | $278K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 5,220 | 19 | $39.24 | $205K |
| J9025 Injection, azacitidine, 1 mg | Office | 4,500 | 11 | $0.30 | $1,356 |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 3,680 | 17 | $45.88 | $169K |
| J0897 Injection, denosumab, 1 mg | Office | 3,480 | 23 | $20.48 | $71K |
| J1930 Injection, lanreotide, 1 mg | Office | 3,360 | 11 | $37.59 | $126K |
| J9267 Injection, paclitaxel, 1 mg | Office | 2,784 | 12 | $0.08 | $221 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,140 | 13 | $31.63 | $68K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,100 | 18 | $15.84 | $33K |
| 85025 Blood Count | Office | 1,576 | 757 | $7.60 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,450 | 77 | $0.09 | $130 |
| 36415 Venipuncture Blood Collection | Office | 1,365 | 688 | $8.64 | $12K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,101 | 11 | $0.11 | $118 |
By year: 2022 $1.9M for 100,462 services; 2023 $3.1M for 154,213 services; 2024 $3.2M for 130,308 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,576 | 757 | $7.60 | $12K |
| 36415 Venipuncture Blood Collection | 1,365 | 688 | $8.64 | $12K |
| 81002 Clinical Chemistry | 85 | 33 | $3.41 | $290 |
| 85610 Clinical Chemistry | 47 | 12 | $4.20 | $197 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher H Chay prescribed most often to Medicare patients was Prednisone, with 300 prescriptions and refills. In total Christopher H Chay wrote 2,308 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 300 | 338 | 83 | $1,338 |
| Abiraterone Acetate Generic | 226 | 232 | 35 | $531K |
| Xtandi Enzalutamide | 95 | 95 | 11 | $1.2M |
| Ondansetron Hcl Generic | 80 | 81 | 42 | $595 |
| Gabapentin Generic | 75 | 107 | 18 | $596 |
| Letrozole Generic | 74 | 140 | 23 | $836 |
| Bicalutamide Generic | 71 | 127 | 21 | $1,806 |
| Eliquis Apixaban | 67 | 83 | 11 | $46K |
| Dexamethasone Generic | 62 | 64 | 23 | $1,346 |
| Ibrance Palbociclib | 60 | 60 | Under 11 | $882K |
| Revlimid Lenalidomide | 58 | 58 | Under 11 | $1.2M |
| Anastrozole Generic | 56 | 140 | 21 | $872 |
| Oxycodone Hcl Generic | 54 | 54 | 24 | $1,222 |
| Omeprazole Generic | 52 | 96 | 17 | $257 |
| Promethazine Hcl Generic | 47 | 47 | 31 | $329 |
Brand drugs: 593 claims; generic drugs: 1,715 claims; opioid claims: 142.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher H Chay $2,511 ($2,511 in general payments such as food, travel and fees) from 33 companies. The largest payer was Caris MPI, Inc. with $1,136.
| Company | Payments | Amount |
|---|---|---|
| Caris MPI, Inc. | 3 | $1,136 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $195 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $133 |
| Janssen Biotech, Inc. JNJ | 5 | $127 |
| Abbvie Inc. ABBV | 5 | $108 |
| Merck Sharp & Dohme LLC MRK | 3 | $83 |
| BeOne Medicines USA, Inc. ONC | 4 | $77.59 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $68.07 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $53.17 |
| Pfizer Inc. PFE | 3 | $48.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.